Second Open Label Extension to Bridging Study CTBM100C2303
NCT01069705
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
49
Enrollment
INDUSTRY
Sponsor class
Conditions
Pulmonary Infections
Pseudomonas Aeruginosa
Interventions
DRUG:
Tobramycin inhalation powder
Sponsor
Novartis Pharmaceuticals